Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis

Abstract

The self-medication hypothesis attempts to explain the extraordinary high levels of cigarette smoking in schizophrenia; patients may smoke in an attempt to reduce their cognitive deficits, symptoms, or the side effects of antipsychotics. In a previous report, we detected beneficial performance in attention and working memory in patients with first-episode psychosis who smoked compared to non-smoking patients soon after stabilization. In the present study, we examine differences in the course of those deficits 12 months after the initiation of antipsychotic treatment. We also explore the association between smoking and symptoms and side effects of medication. Neuropsychological assessments were performed at baseline, month 6 and month 12 using a computerized battery that included measures of sustained attention (Continuous Performance Test CPT-O), selective attention (Stroop interference task) and working memory (CPT-XO). Patients met the criterion of fitting in the same smoking category throughout the study: non-smoker (n = 15; 0 cigarettes/day) and smoker (n = 26; >15 cigarettes/day). The non-smoking patients showed significant cognitive improvements, whereas smoking patients lost their superior baseline performance, which was probably obtained through nicotinic stimulation, at the 6- and 12-month assessments due to a static course of deficits. Smokers did not obtain any cognitive benefit after instauration of treatment and worsen their symptoms over the first year. These results suggest that smoking may constitute a marker of a more severe illness. Smoking was not associated with fewer extrapyramidal side effects. Smoking might improve attention and working memory to a similarly modest extent as atypical antipsychotics and could reflect an effort to ameliorate these cognitive dysfunctions previous to treatment instauration.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Adler LE, Hoffer LD, Wiser A, Freedman R (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150(12):1856–1861

    PubMed  CAS  Google Scholar 

  2. 2.

    Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32(7):607–616

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24(2):189–202

    PubMed  CAS  Google Scholar 

  4. 4.

    Aguilar MC, Gurpegui M, Diaz FJ, de Leon J (2005) Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. Br J Psychiatry 186:215–221

    PubMed  Article  Google Scholar 

  5. 5.

    AhnAllen CG, Nestor PG, Shenton ME, McCarley RW, Niznikiewicz MA (2008) Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia. Schizophr Res 100(1–3):261–269

    PubMed  Article  Google Scholar 

  6. 6.

    Avila MT, Sherr JD, Hong E, Myers CS, Thaker GK (2003) Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 28(12):2184–2191

    PubMed  CAS  Google Scholar 

  7. 7.

    Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF, Freudenreich O, Goff DC, Evins AE (2008) The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33:480–490

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Beratis S, Katrivanou A, Gourzis P (2001) Factors affecting smoking in schizophrenia. Compr Psychiatry 42(5):393–402

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Brewer WJ, Wood SJ, Phillips LJ, Francey SM, Pantelis C, Yung AR, Cornblatt B, McGorry PD (2006) Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull 32(3):538–555

    PubMed  Article  Google Scholar 

  10. 10.

    Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23(2):119–127

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166(6):675–682

    PubMed  Article  Google Scholar 

  12. 12.

    de Leon J, Diaz FJ (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76(2–3):135–157

    PubMed  Article  Google Scholar 

  13. 13.

    de Leon J, Diaz FJ, Aguilar MC, Jurado D, Gurpegui M (2006) Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. Schizophr Res 86(1–3):256–268

    PubMed  Article  Google Scholar 

  14. 14.

    Depatie L, O’Driscoll GA, Holahan AL, Atkinson V, Thavundayil JX, Kin NN, Lal S (2002) Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 27(6):1056–1070

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Dervaux A, Laqueille X (2007) Tobacco and schizophrenia: therapeutic aspects. Encephale 33(4 Pt 1):629–632

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Dervaux A, Laqueille X (2008) Smoking and schizophrenia: epidemiological and clinical features. Encephale 34(3):299–305

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Ettinger U, Williams SC, Patel D, Michel TM, Nwaigwe A, Caceres A, Mehta MA, Anilkumar AP, Kumari V (2009) Effects of acute nicotine on brain function in healthy smokers and non-smokers: estimation of inter-individual response heterogeneity. Neuroimage 45(2):549–561

    PubMed  Article  Google Scholar 

  18. 18.

    First M, Spittzer R, Gibbon M, Williams J (1995) Structured clinical interview for DSM-IV axis I disorders, patient ediction (SCID-P). Version 2. N. Y. S. P. Institute, Biometrics Research, New York

  19. 19.

    Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94(2):587–592

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE (2002) Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26(1):75–85

    PubMed  Article  Google Scholar 

  21. 21.

    Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, Zerbe G, Freedman R (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29(7):1378–1385

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Hutton SB, Ettinger U (2006) The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology 43(3):302–313

    PubMed  Article  Google Scholar 

  23. 23.

    Imperato A, Obinu MC, Casu MA, Mascia MS, Dazzi L, Gessa GL (1993) Evidence that neuroleptics increase striatal acetylcholine release through stimulation of dopamine D1 receptors. J Pharmacol Exp Ther 266(2):557–562

    PubMed  CAS  Google Scholar 

  24. 24.

    Jacobsen LK, D’Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH (2004) Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 55(8):850–858

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64(6):633–647

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA (2007) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164(7):1061–1071

    PubMed  Article  Google Scholar 

  27. 27.

    Kelly C, McCreadie RG (1999) Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 156(11):1751–1757

    PubMed  CAS  Google Scholar 

  28. 28.

    Kumari V, Postma P (2005) Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 29(6):1021–1034

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R (2002) Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59(12):1085–1096

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Levin ED, Wilson W, Rose JE, McEvoy J (1996) Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15(5):429–436

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Lieberman JA, Javitch JA, Moore H (2008) Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry 165(8):931–936

    PubMed  Article  Google Scholar 

  32. 32.

    Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Mansvelder HD, van Aerde KI, Couey JJ, Brussaard AB (2006) Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl) 184(3–4):292–305

    Article  CAS  Google Scholar 

  34. 34.

    Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22(1–2):115–126

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA, Thaker GK (2004) Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 174(3):334–340

    Article  CAS  Google Scholar 

  37. 37.

    Olincy A, Johnson LL, Ross RG (2003) Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 117(3):223–236

    PubMed  Article  Google Scholar 

  38. 38.

    Peralta V, Cuesta M (1994) Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso-Esp Neurol Psiquiatr 22(4):171–177

    Google Scholar 

  39. 39.

    Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62(6):649–659

    PubMed  Article  Google Scholar 

  40. 40.

    Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK (2002) The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 52(7):721–728

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002) Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27(3):479–497

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Smith RC, Warner-Cohen J, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S, Khan A (2006) Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31(3):637–643

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD (2006) Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 81(2–3):145–150

    PubMed  Article  Google Scholar 

  45. 45.

    Weiser M, Reichenberg A, Grotto I, Yasvitzky R, Rabinowitz J, Lubin G, Nahon D, Knobler HY, Davidson M (2004) Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry 161(7):1219–1223

    PubMed  Article  Google Scholar 

  46. 46.

    Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, Pinto AG, Gutierrez M (2009) Cognitive performance and cigarette smoking in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci 259(2):65–71

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

Funding for this study was provided by grants: 2008111010 (Department of Health of the Basque Government, Healthcare Research Fund), UPV-EHU GIU09/37; GIU07/07 and UPV-EHU post doctoral grant to A. Zabala (University of the Basque Country), PI05/1508; PI07/0245; PI08/1130 (Instituto de Salud Carlos III) and by the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). None of the funding sources had further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. We wish to thank Dr. JJ Meana and Dr. LF Callado for comments on the manuscript.

Conflict of interest

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Arantzazu Zabala.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Segarra, R., Zabala, A., Eguíluz, J.I. et al. Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis. Eur Arch Psychiatry Clin Neurosci 261, 241–250 (2011). https://doi.org/10.1007/s00406-010-0146-6

Download citation

Keywords

  • First-episode psychosis
  • Cognitive deficits
  • Cigarette smoking
  • Nicotine
  • Self-medication